AstraZeneca (LSE: AZN) has announced that the immuno-oncology drug Imfinzi (durvalumab), under development by the Anglo-Swedish firm’s biotech arm MedImmune, has performed well in a pivotal trial in lung cancer.
The company's share price rose almost 5% on the news.
The immuno-oncology candidate Imfinz (/durvalumab) was trailed asas a second-line treatment for certain non-small cell lung cancer (NSCLC) patients.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze